Gold tier: mechanically validated evidence, with its primary source.
206 evidence items · page 9 / 9
SARS-CoV-2 clearance was similar between malaria co-infected and non-co-infected groups by day 28 (adjusted risk ratio 0.99 [95% CI 0.79–1.24]; p=0.95).
KenyaCOVID-19 · paludismeobserved by day 28published 2026The Lancet. Global healthPubMeddocument of 8 observations
17 %Among adolescents living with HIV in Kenya, 17% reported no longer being able to go to their regular clinic for medical care due to COVID-19.
KenyaCOVID-19published 2021AIDS and behaviorPubMeddocument of 6 observations
23 %Among adolescents living with HIV in Kenya, 23% reported no longer being able to go outside due to COVID-19.
KenyaCOVID-19published 2021AIDS and behaviorPubMeddocument of 6 observations
32.4 %In Nairobi, seroprevalence of anti-SARS-CoV-2 IgG was 32.4% (95% CI 23.1–42.4%) at the beginning of the study period.
KenyaCOVID-19published 2022PLOS global public healtheurope_pmcdocument of 7 observationsDOI 10.1371/journal.pgph.0000883
29 lineages29 Pango lineages were detected across six counties of Coastal Kenya during Wave 2 of SARS-CoV-2 infections.
KenyaCOVID-19observed Wave 2published 2022eLifeeurope_pmcdocument of 6 observations
37 casesAmong 97 SARS-CoV-2 cases in Laikipia county, Kenya, the Omicron variant was detected in 37 cases.
KenyaCOVID-19observed 24th April to 31st December 2021published 2023Temporal distribution and clinical characteristics of the Alpha, Delta and Omicron SARS-Coeurope_pmcdocument of 10 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.